Loading...
•
Dec 31, 2024
Aura Biosciences Q4 2024 Earnings Report
Aura Biosciences reported a net loss in Q4 2024 with increased R&D and G&A expenses as clinical trials progressed.
Key Takeaways
Aura Biosciences posted a Q4 2024 net loss of $25.8 million, with no reported revenue. The company continued investing in clinical trials and manufacturing for its lead candidate bel-sar, resulting in higher R&D and G&A expenses. Cash and marketable securities totaled $151.1 million, expected to fund operations into the second half of 2026.
EPS for Q4 2024 was -$0.52, missing estimates by $0.08.
Net loss reached $25.8M, up from $22.1M in Q4 2023.
R&D expenses rose to $22.3M due to ongoing trials and manufacturing.
Cash and marketable securities totaled $151.1M at quarter-end.
Aura Biosciences
Aura Biosciences
Forward Guidance
Aura anticipates continued advancement of its bel-sar program with clinical data expected in 2025 and sufficient funding through the second half of 2026.
Positive Outlook
- Cash runway expected into 2H 2026
- Positive clinical data presented in NMIBC
- Phase 3 CoMpass trial actively enrolling
- FDA Fast Track designation for multiple indications
- Broad expansion into ocular and bladder oncology
Challenges Ahead
- No revenue generation in Q4 2024
- Increased operating expenses driven by trial costs
- Wider net loss compared to prior year
- High dependency on clinical trial outcomes
- No approved therapies currently generating income